---
document_datetime: 2023-09-21 21:52:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/byfavo-epar-all-authorised-presentations_en.pdf
document_name: byfavo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7787841
conversion_datetime: 2025-12-22 13:40:40.877575
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                                        | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|------------------------------------------------------------|---------------------------|-----------------------|-------------|
| EU/1/20/1505/001 | Byfavo            | 20 mg      | Powder for solution for injection                          | Intravenous use           | vial (glass)          | 10 vials    |
| EU/1/20/1505/002 | Byfavo            | 50 mg      | Powder for concentrate for solution for infusion/injection | Intravenous use           | vial (glass)          | 10 vials    |